Sana Biotechnology (NASDAQ:SANA) Trading Up 5.7% – Still a Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA) rose 5.7% during mid-day trading on Monday . The company traded as high as $4.01 and last traded at $3.87. Approximately 2,159,066 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 32,192,027 shares. The stock had previously closed at $3.66.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SANA shares. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright boosted their price target on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sana Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Price Performance

The stock has a market cap of $810.47 million, a PE ratio of -2.59 and a beta of 1.45. The company’s fifty day moving average is $2.40 and its 200-day moving average is $4.02.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Insider Buying and Selling

In related news, insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sana Biotechnology by 17.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after purchasing an additional 5,338 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Sana Biotechnology by 2.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock valued at $1,056,000 after buying an additional 6,823 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $29,000. Arizona State Retirement System lifted its position in shares of Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after buying an additional 9,940 shares in the last quarter. Finally, Stifel Financial Corp acquired a new stake in Sana Biotechnology in the 3rd quarter valued at $43,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.